Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00084734 · ClinicalTrials.gov registry record · Phase 1
Docetaxel, Capecitabine, and Cisplatin in Treating Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Roswell Park Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 61
- Enrollment target
NCT00084734 is a Phase 1 study that has completed, run by Roswell Park Cancer Institute. The registered enrollment target is 61 participants.
The verdict
NCT00084734, a Phase 1 study, has completed, sponsored by Roswell Park Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 61 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as docetaxel, capecitabine, and cisplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Giving more than one chemotherapy drug may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of docetaxel, capecitabine, and cisplatin in treating patients with metastatic or unresectable solid tumors.
Interventions
- DRUG cisplatin
- DRUG docetaxel
- DRUG capecitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2002-05 |
| Est. Completion | 2009-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00084734
The ClinicalTrials.gov registry entry for NCT00084734 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which cisplatin is the first listed.
NCT00084734 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00084734 about?
NCT00084734 is a clinical study titled "Docetaxel, Capecitabine, and Cisplatin in Treating Patients With Advanced Solid Tumors". RATIONALE: Drugs used in chemotherapy, such as docetaxel, capecitabine, and cisplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Giving more than one chemotherapy drug may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and...
What is the current status of trial NCT00084734?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 61 participants. The study started on 2002-05. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00084734?
The interventions under investigation include: cisplatin (DRUG), docetaxel (DRUG), capecitabine (DRUG).
Who is sponsoring clinical trial NCT00084734?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.